Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer
Dr. Hava brings more than a decade of senior experience in research and development to Synlogic, including deep academic expertise in pillars of synthetic biology. Prior to joining Synlogic, David served as CSO at Metera Pharmaceuticals. David has also served as CSO at Pulmatrix Inc., where he led the Research and Development organization in the company’s development of their delivery platform. David has co-authored dozens of papers and abstracts focusing on immunology, pulmonary infectious disease and chronic lung diseases, advanced four assets into the clinic, and executed multiple value creating research and clinical partnerships.
Dr. Hava earned his Ph.D. in Molecular Biology and Microbiology at Tufts University and completed his post-doctoral training at Harvard Medical School studying immunology and host-pathogen interactions.
About Synlogic
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic’s proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.